Hanmi Pharmaceutical announced that it recorded sales of 1.11 trillion Korean won ($937 million), an operating profit of 104 billion Korean won and a net profit of 63.9 billion Korean won in the last year. For the first time Hanmi Pharmaceutical’s operating profits surpassed 100 billion Korean won, with the help of the accumulated gains from its technology exports since 2015.
Hanmi Pharmaceutical’s sales majorly boosted because of it 3 best products namely – Amozaltan family which is a hypertension therapy complex drug, Rosuzet which is a hyperlipidemia therapy complex new drug, and Esomezol which is reflux esophagitis therapy new drug. As per the consolidated financial statements, Hanmi Science, a part of Hanmi Pharmaceuticals Group has registered sales of 816.6 billion Korean won, also an operating profit of 38 billion Korean won and net profit of 30.7 billion won in the year of 2019.
Beijing Hanmi Pharmaceutical’s sales also improved and reached to 254.4 billion Korean won, the operating profit reached to 43.6 billion Korean won, and net profit was 37.4 billion Korean won. Wu Jong-Soo, the President of Hanmi Pharmaceutical said that they will soon accelerate their challenge of become a world-class pharmaceutical company with innovative as well as sustainable growth.